| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000007174 |
| Receipt No. | R000008452 |
| Official scientific title of the study | Research study of time interval of live vaccination in post KD IVIG |
| Date of disclosure of the study information | 2012/01/31 |
| Last modified on | 2017/02/03 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Research study of time interval of live vaccination in post KD IVIG | |
| Title of the study (Brief title) | Research study of time interval of live vaccination in post KD IVIG | |
| Region |
|
|
| Condition | ||||
| Condition | Kawasaki Disease | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | We are aimed at confirming the vaccination response and the transition of antibody titer in the children who received measles, rubella, mumps and VZV vaccination after IVIG for Kawasaki disease by the method recommended from Ministry of Health, Labor and Welfare in Japan. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The ratio of acquisition of immunity |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Children who received IVIG for Kawasaki disease
Children who were not affected measles, rubella, mumps and VZV Children who have not got vaccination of measles, rubella, mumps and VZV Six months to 6 years old. Written consent from the parents |
|||
| Key exclusion criteria | Positive one or more of antibody titer of measles, rubella, mumps or VZV on the examination at the admission.
Malignancy diseases, immune deficiency disease or chromosomal abnormality. Received immunosuppressant or systemic steroid within one month to be hospitalized as Kawasaki disease. Chronic Kidney disease. Judged inappropriate for this study by the physicians. |
|||
| Target sample size | 50 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroshi Sakakibara |
| Organization | Tokyo Metropolitan Children's Medical Center |
| Division name | Division of General Pediatrics |
| Address | 2-8-29 Musashidai Fuchu-shi Tokyo |
| TEL | 042-300-5111 |
| yoshihiko_morikawa@tmhp.jp | |
| Public contact | |
| Name of contact person | Yoshihiko Morikawa |
| Organization | Tokyo Metropolitan Children's Medical Center |
| Division name | Division of clinical research |
| Address | 2-8-29 Musashidai Fuchu-shi Tokyo |
| TEL | 042-300-5111 |
| Homepage URL | |
| yoshihiko_morikawa@tmhp.jp | |
| Sponsor | |
| Institute | Tokyo Metropolitan Children's Medical Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Clinical research of Tokyo metropolitan hospital group |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Evaluation to antibody titer of measles, rubella, mumps and VZV 3 months and 6 months after IVIG.
Administrate of measles, rubella, mumps and VZV 6 months after IVIG, and then evaluate the titers 3 months after vaccination. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000008452 |